Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26634180
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Aripiprazole for Treatment of Apathy
#MMPMID26634180
Monga V
; Padala PR
Innov Clin Neurosci
2015[Sep]; 12
(9-10
): 33-6
PMID26634180
show ga
OBJECTIVE: The objective of this article is to present a case of improved outcome
of apathy syndrome with aripiprazole. CASE SUMMARY: A 42-year-old man with
depression and seizure disorder had significant apathy that did not respond to
carbamazepine, sertraline, and topiramate. Apathy was assessed using Apathy
Evaluation Scale. Discontinuation of carbamazepine did not alleviate apathy.
Aripiprazole, a novel antipsychotic with partial agonistic activity at dopamine
D2 receptors, was introduced and the dose adjusted to 15mg a day. The patient
showed significant improvement in apathy after six weeks of therapy with
aripiprazole. DISCUSSION: Depression is often mistaken for apathy, which is
different in symptoms, presentation, and treatment options. Selective serotonin
reuptake inhibitors are known to cause or increase symptoms of apathy in some
patients. Recent evidence suggests that dopamine receptor agonists can be helpful
in treatment of apathy. Apathy significantly improved in this patient after
initiation of aripiprazole. CONCLUSION: Aripiprazole may be useful for treatment
of apathy syndrome. Its role in treatment of apathy requires further
investigation in clinical trials.
free
free
free
